Unichem Laboratories Limited announced that it has received ANDA approval for its Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Ranexa®? (ranolazine extended-release tablets) 500 mg and 1,000 mg, of Gilead Sciences Inc. Ranolazine Extended-Release Tablets, 500 mg, and 1,000 mg are indicated for the treatment of chronic angina. The product will be commercialized from Unichem's Goa Plant.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
532 INR | -1.33% |
|
-2.87% | +30.74% |
1st Jan change | Capi. | |
---|---|---|
+30.74% | 455M | |
+52.93% | 803B | |
+40.98% | 631B | |
-7.08% | 351B | |
+17.40% | 324B | |
+10.58% | 303B | |
+16.42% | 243B | |
+2.17% | 228B | |
+10.66% | 217B | |
+6.24% | 164B |
- Stock Market
- Equities
- UNICHEMLAB Stock
- News Unichem Laboratories Limited
- Unichem Laboratories Limited Receives ANDA Approval for its Ranolazine Extended-Release Tablets, 500 Mg and 1,000 Mg from the United States Food and Drug Administration